Prognostic role of long non-coding RNA XIST expression in patients with solid tumors: a meta-analysis.

Cancer Cell Int

1Comprehensive Laboratory, Changzhou Key Lab of Individualized Diagnosis and Treatment Associated with High Technology Research, The Third Affiliated Hospital of Soochow University, Changzhou, 213003 China.

Published: March 2018

AI Article Synopsis

  • The study examined the role of long non-coding RNA (lncRNA) XIST in cancer, highlighting its connection to tumor growth and survival rates.
  • Researchers conducted a meta-analysis of 15 studies with over 1200 cancer patients, finding that high lncRNA XIST expression was linked to worse overall survival (OS) outcomes, particularly in digestive system tumors.
  • The findings suggest that lncRNA XIST could serve as a poor prognostic biomarker, offering insights for future cancer diagnostics and treatment strategies.

Article Abstract

Background: The aberrant expression of long non-coding RNA (lncRNA) X inactivate-specific transcript (XIST) has been demonstrated to be involved in the tumourigenesis and the development of various cancers. Therefore, we conducted a meta-analysis to assess the prognostic role of lncRNA XIST expression in solid tumors.

Methods: The databases of PubMed, EMBase, Web of Science, Cochrane library (up to Dec 31, 2017) were searched for the related studies and identified 15 eligible studies containing 1209 patients to include in the meta-analysis. Hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to estimate the association between lncRNA XIST expression and survival of cancer patients from Asian.

Results: The result showed that higher lncRNA XIST expression in cancer tissue was related to a worse overall survival (OS) (HR = 1.54, 95% CI 1.07-2.23). In subgroup analysis, it revealed that lncRNA XIST overexpression was significantly associated with worse OS in digestive system tumors (HR = 1.67, 95% CI 1.11-2.51, = 0.031). In addition, the association between high lncRNA XIST expression and poor OS was also statistically significant in other subgroups, including multivariate analysis (HR = 2.39, 95% CI 1.28-4.46, = 0.006, random-effect), patients' number was greater than 65 (HR = 1.75, 95% CI 1.24-2.47, = 0.001, random-effect), and reported in text (HR = 2.50, 95% CI 1.49-4.18, = 0.000, random-effect).

Conclusions: The expression of lncRNA XIST could be regarded as a poor prognostic biomarker for solid tumors, which might shed new light on epigenetic diagnostics and therapeutics in tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845363PMC
http://dx.doi.org/10.1186/s12935-018-0535-xDOI Listing

Publication Analysis

Top Keywords

lncrna xist
24
xist expression
20
prognostic role
8
long non-coding
8
non-coding rna
8
xist
8
solid tumors
8
expression
7
lncrna
7
95%
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!